Shares of BioNTech BNTX rose 8.3% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 2134.62% over the past year to $5.29, which beat the estimate of $3.72.
Revenue of $2,470,000,000 up by 7995.18% year over year, which beat the estimate of $1,780,000,000.
Looking Ahead
BioNTech hasn't issued any earnings guidance for the time being.
BioNTech hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 10, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/kydee3w8
Recent Stock Performance
Company's 52-week high was at $213.15
Company's 52-week low was at $45.08
Price action over last quarter: Up 82.16%
Company Profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.